Eli Lilly's Strattera approved for ADHD maintenance in kids

By Associated Press May 8, 2008 Comments (0)

0 Recommendations

Eli Lilly and Co. said Thursday the Food and Drug Administration approved its drug Strattera for maintenance of attention-deficit/hyperactivity disorder in children and adolescents.

The company said Strattera is the first FDA-approved non-stimulant to treat ADHD in children, adolescents and adults. Stimulant drugs currently on the market include Shire Pharmaceuticals' Adderall and Novartis' Ritalin.

ADHD is one of the most common mental health disorders in children and adolescents. Lilly said long-term studies showed Strattera provides uninterrupted relief from ADHD symptoms beyond the school day into the evening.

Lilly did note that Strattera has been shown to increase the risk of suicidal thoughts in some children and teens, with a combined analysis of 12 studies showing the risk was 0.4 percent compared with none for those taking a sugar pill. A similar analysis in adults treated with Strattera did not reveal increased risk of suicidal thoughts.

Comments (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.

Be the first one to comment on this article.

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Compare Brokers

DocumentId: 640398, ~/articles/articlehandler.aspx, 7/9/2008 2:25:29 AM, No ticker

FREE 1-Step Fool.com Access!

Already registered? Login Here

No, thanks

Simply enter your email address below to get:

Instant access to this article and all in-depth Motley Fool news and analysis.
A FREE FoolWatch Weekly email subscription — save time by getting the very best Motley Fool features and market coverage handpicked by Fool.com editors and delivered to you each week.

Privacy / Legal Information